Highlights

  • Noxopharm reported US FDA feedback on its proposed Phase II study for SOF-SKN in October 2026.
  • The company is preparing a cutaneous lupus erythematosus extension study following a Phase I study.
  • The planned extension study involves approximately 15 patients and a defined topical dosing period.
  • August preclinical research examined immune responses to dying cancer cells using Sofra oligonucleotides.
  • Clinical development remains subject to regulatory, manufacturing and study requirements.

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage biotechnology company developing treatments for inflammation, autoimmune disease and cancer. Its Sofra platform investigates synthetic oligonucleotides that regulate immune signalling, while its Chroma platform concentrates on oncology drug candidates. The company’s 2026 disclosures place SOF-SKN clinical preparations and early-stage immuno-oncology research at the centre of its development activities.

FDA Feedback Shapes the SOF-SKN Program

On 8 October 2026, Noxopharm Limited (ASX:NOX) disclosed that the US Food and Drug Administration had provided feedback on plans for a Phase II clinical trial of SOF-SKN. The regulator considered the proposed trial design reasonable and was supportive of the company’s manufacturing approach. It also provided guidance on non-clinical studies and the information needed for a future Investigational New Drug application.

The feedback does not constitute drug approval or authorisation to begin Phase II. Noxopharm Limited (ASX:NOX) targets the trial for the first half of calendar 2028, conditional on regulatory, clinical and manufacturing requirements. The company must complete the relevant preparatory work and incorporate the regulator’s comments before progressing its submission.

Cutaneous Lupus Study Plans for 2027

In September 2026, Noxopharm Limited (ASX:NOX) outlined a proposed SOF-SKN extension study in people with cutaneous lupus erythematosus, an autoimmune condition affecting the skin. The company reported completion of its first-in-human HERACLES Phase I trial in healthy volunteers in January 2026. The next study is intended to assess safety, tolerability and preliminary signs of efficacy in the patient population.

The planned extension study is designed to enrol approximately 15 patients, each receiving 14 days of daily topical treatment followed by seven days of observation. Noxopharm Limited (ASX:NOX) targets commencement in Q1 CY27, initial efficacy signals in Q2 CY27 and a fuller clinical readout in Q4 CY27. These are company timelines, dependent on enrolment, ethics approval and other requirements; they are not reported outcomes.

Sofra Research Extends Into Immuno-Oncology

Separate laboratory research announced on 26 August 2026 explored whether Sofra oligonucleotides could help immune cells recognise dying cancer cells. Noxopharm Limited (ASX:NOX) reported increased immune activation when an experimental TLR8-amplifying oligonucleotide was combined with dying cancer cells, compared with a condition without the oligonucleotide.

The findings are preclinical and do not establish patient benefit. The company described them as support for further investigation, including studies in living models. This work differs from SOF-SKN’s skin-disease clinical program, although both draw on Sofra’s approach to immune signalling.

Development Risks and Evidence Requirements

Key uncertainties include whether early safety observations translate to patients, whether the planned lupus study shows clinically meaningful effects, and whether manufacturing and regulatory requirements can be met. Laboratory immune activation also cannot establish cancer-treatment effectiveness. Noxopharm Limited (ASX:NOX) remains exposed to the costs and timelines associated with developing medicines before any potential commercial use.

Key Insights

Noxopharm Limited (ASX:NOX) has described a defined sequence of 2026 regulatory discussions, planned patient studies and preclinical work. The distinction between FDA feedback, early clinical testing and laboratory findings is central to interpreting the company’s disclosures. Further results will be needed to assess safety, efficacy and the feasibility of later development stages.